Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07237048 · ClinicalTrials.gov registry record · Phase 2
Minocycline in Stroke Study at Maimonides
A Phase 2 study of Stroke and Mortality, sponsored by Joyce Chen.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 1,164
- Enrollment target
- 1
- Study location
NCT07237048: Recruiting Phase 2 study of Stroke and Mortality, sponsored by Joyce Chen.
NCT07237048 is a Phase 2 study of Stroke and Mortality that is actively recruiting participants, run by Joyce Chen. The registered enrollment target is 1,164 participants, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07237048, a Phase 2 study of Stroke and Mortality, is actively recruiting participants, sponsored by Joyce Chen.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 1,164 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*National Institutes of Health Stroke Scale\* (NIHSS) scores at hospital discharge and 90 days post-stroke? 2. Does Minocycline reduce stroke-related disability, all-cause in hospital mortality (mRS -\*Modified Rankin Scale\* = 6) and at 90 days besides reducing brain bleeding complications compared to standard care? Researchers will compare patients receiving oral Minocycline plus standard care to those receiving standard care only to see if Minocycline leads to better neurological outcomes and lower mortality. Participants will: 1. Be randomly assigned by block to receive either: Minocycline 200 mg orally once daily for five days within 24 hours from symptoms onset + Standard Care, or Standard Care only 2. Undergo neurological assessments using NIHSS \*National Institutes of Health Stroke Scale\* and Modified Rankin Scale (mRS) at admission, discharge, 30 days post-stroke, 90 days post-stroke 3. Be monitored for: a) hemorrhagic transformation of ischemic strokes; b) Adverse events and mortality outcomes; c) Safety and efficacy signals through interim analyses NIHSS: \*National Institutes of Health Stroke Scale\*, which is stroke severity scale, mRS: \*Modified Rankin Scale\*, which is stroke disability scale
Primary Outcome
The NIHSS score will be assessed at Day 7 post-stroke to measure neurological impairment and recovery. The primary outcome is the difference in NIHSS scores between the Minocycline plus standard care group and the standard care alone group.
Conditions Studied
Interventions
- DRUG Minocycline 200mg
Study Locations (1)
New York
- Maimonides Medical Center - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,164 participants |
| Start Date | 2026-02-02 |
| Est. Completion | 2028-12 |
| Phase | Phase 2 |
What NCT07237048 shows while recruiting
NCT07237048 is an interventional study that assigns participants to a tested intervention. Its 1,164 participants enrollment target places it among the larger protocols in the corpus, below the 12,014-participant average among 454 other Stroke trials with a reported enrollment target (90% lower).
The record links to 7 conditions, with Stroke appearing as the primary indexed condition, and to 1 intervention - of which Minocycline 200mg is the first listed.
NCT07237048 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07237048 about?
NCT07237048 is a clinical study titled "Minocycline in Stroke Study at Maimonides". The goal of this study is to determine if Minocycline, when added to standard care, can improve survival and functional outcomes in patients with moderate acute stroke (ischemic or hemorrhagic) aged 18 years and older. The main questions it aims to answer are: 1. Does Minocycline improve \*Nationa...
What is the current status of trial NCT07237048?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 1,164 participants. The study started on 2026-02-02. Estimated completion is 2028-12.
What conditions does trial NCT07237048 study?
This clinical trial studies the following conditions: Stroke, Mortality, Hemorrhagic Strokes, Morbidity, Intracerebral Haemorrhage (ICH).
What interventions are being tested in trial NCT07237048?
The interventions under investigation include: Minocycline 200mg (DRUG).
Who is sponsoring clinical trial NCT07237048?
This trial is sponsored by Joyce Chen, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07237048 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07237048's enrollment target sits among peer trials
1,164 35th of 454 higher than 420 of 454 other Stroke trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stroke trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wearable Biofeedback for Swallowing Disorders Rehabilitation in Stroke and Parkinson Disease
RECRUITING · Phase 2
-
Balancing Effortful and Errorless Learning in Naming Treatment for Aphasia
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Mild Aphasia
RECRUITING · Phase 2
-
Novel Wrist Sensor System to Promote Hemiparetic Arm Use in Home Daily Life of Chronic Stroke Survivors
RECRUITING · Phase 2
-
Transcranial Magnetic Stimulation + Language Therapy to Treat Subacute Aphasia
RECRUITING · Phase 2
-
Myofascial Dysfunction in Post Stroke Shoulder Pain
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07009509 · 1,166 participants · NA
Pilot Study of the YES-CAN! Program to Prevent Youth Nicotine Vaping
- NCT04577599 · 1,160 participants · NA
Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54
- NCT07082738 · 1,160 participants · Phase 2
A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- NCT06469788 · 1,170 participants · NA
Testimonials and Navigation in Rheumatology
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI